A targeted sequencing analysis of 21 cSCC samples collected from patients receiving the BRAF inhibitor vemurafenib identified activating RAS mutations in 60% of the tumor samples, with HRAS being more commonly affected than other members of the RAS family, indicating the potent effect of BRAF repression on the other signaling molecules involved in RAS/RAF/MEK/ERK pathway [38,39]. Here, BRAF is linked to neoplasm.